NASDAQ : RLAY
Relay Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 19.47 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 4.27B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 4.02B |
| Enterprise Value | 3.14B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 219.14M |
| Shares Outstanding | 219.14M |
| Shares Change (YoY) | +12.39% |
| Shares Change (QoQ) | +12.79% |
| Owned by Insiders (%) | 1.62% |
| Owned by Institutions (%) | 91.94% |
| Float | 145.54M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 388.53 |
| Forward PS | 379.54 |
| PB Ratio | 4.51 |
| P/TBV Ratio | 4.52 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 303.48 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 18.27 |
| Quick Ratio | 17.93 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -36.77% |
| Return on Assets (ROA) | -22.88% |
| Return on Invested Capital (ROIC) | -23.95% |
| Return on Capital Employed (ROCE) | -33.87% |
| Weighted Average Cost of Capital (WACC) | 13.67% |
| Revenue Per Employee | $51,238 |
| Profits Per Employee | -$1.42M |
| Employee Count | 202 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.73 |
| 52-Week Price Change | +151.03% |
| 50-Day Moving Average | 18.52 |
| 200-Day Moving Average | 15.00 |
| Relative Strength Index (RSI) | 49.99 |
| Average Volume (20 Days) | 2,435,160 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 44.03M |
| Short Previous Month | 46.75M |
| Short % of Shares Out | 20.09% |
| Short % of Float | 30.25% |
| Short Ratio (days to cover) | 13.49 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 10.35M |
| Gross Profit | -258.50M |
| Operating Income | -310.44M |
| Pretax Income | -286.04M |
| Net Income | -286.04M |
| EBITDA | -308.22M |
| EBIT | -310.44M |
| Loss Per Share | -$1.57 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 910.93M |
| Total Debt | 30.66M |
| Net Cash | 880.28M |
| Net Cash Per Share | $4.02 |
| Equity (Book Value) | 890.01M |
| Book Value Per Share | 4.07 |
| Working Capital | 877.28M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -212.21M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 2.21M |
| Net Borrowing | n/a |
| Free Cash Flow | -212.21M |
| FCF Per Share | -$0.97 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -2,999.37% |
| Pretax Margin | -2,763.64% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -12.39% |
| Shareholder Yield | -12.39% |
| Earnings Yield | -8.56% |
| FCF Yield | -5.28% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $27.58 |
| Price Target Difference | 50.30% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | 32.17% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 9.19 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |